000640.KS
Dong-A Socio Holdings Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 94,000.00
+1.40%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1517.9B | 1429.8B | 1333.2B | 1132.0B | 1014.9B |
| Cost of Revenue | 1044.0B | 990.3B | 925.2B | 757.1B | 720.5B |
| Gross Profit | 473.9B | 439.5B | 408.1B | 374.9B | 294.4B |
| Operating Expenses | |||||
| R&D Expense | 11.0B | 9.5B | 8.9B | 7.4B | 6.4B |
| SG&A Expense | 288.5B | 204.1B | 299.9B | 274.6B | 232.8B |
| General & Admin Expense | 123.8B | 66.6B | 60.9B | 57.3B | 41.5B |
| Selling & Marketing Expense | 69.1B | 137.6B | 129.5B | 113.7B | 93.3B |
| Other Expenses | 71.8B | 128.1B | — | 16.0B | — |
| Total Operating Expenses | 366.5B | 341.7B | 308.8B | 298.0B | 239.2B |
| Cost and Expenses | 1410.5B | 1332.0B | 1251.1B | 1055.1B | 977.0B |
| Operating Income (EBIT) | 107.4B | 97.8B | 82.1B | 76.9B | 37.9B |
| Non-Operating | |||||
| Interest Income | 6.7B | 3.0B | 4.0B | 4.4B | 2.5B |
| Interest Expense | 24.8B | 28.7B | 29.3B | 22.7B | 14.9B |
| Net Interest Income | (18.1B) | (25.6B) | (25.4B) | (18.4B) | (12.4B) |
| Other Non-Op Income/Expense | (22.8B) | (43.7B) | (5.8B) | (11.1B) | (20.2B) |
| Non-Operating Income (excl Interest) | 15.1B | — | (23.5B) | 9.7B | 20.5B |
| EBT (Pre-Tax Income) | 84.5B | 54.1B | 76.3B | 65.7B | 17.6B |
| Income Tax Expense | (348.1M) | (37.4B) | 18.8B | 9.9B | 9.8B |
| Bottom Line | |||||
| Net Income | 85.3B | 90.9B | 58.0B | 58.0B | 11.2B |
| Earnings from Cont. Ops | 84.9B | 91.5B | 57.6B | 55.9B | 7.8B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 85.3B | 90.9B | 58.0B | 58.0B | 11.2B |
| Per Share | |||||
| Basic EPS | ₩12,512 | ₩13,718 | ₩9,012 | ₩9,007 | ₩1,732 |
| Diluted EPS | ₩12,512 | ₩13,718 | ₩9,012 | ₩9,007 | ₩1,732 |
| Revenue Per Share | ₩225,536 | ₩218,719 | ₩207,088 | ₩181,091 | ₩157,612 |
| Shares | |||||
| Basic Shares Outstanding | 6.7M | 6.5M | 6.4M | 6.3M | 6.4M |
| Diluted Shares Outstanding | 6.7M | 6.5M | 6.4M | 6.3M | 6.4M |
| Profitability Metrics | |||||
| EBITDA | 199.7B | 193.1B | 194.9B | 141.4B | 88.1B |
| D&A | 92.3B | 95.4B | 89.2B | 74.2B | 70.7B |
| EBIT | 107.4B | 97.8B | 105.6B | 67.2B | 17.4B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026